SG11202105197UA - Cd70 and venetoclax, a bcl-2 inhibitor, combination therapy for treating acute myeloid leukemia - Google Patents

Cd70 and venetoclax, a bcl-2 inhibitor, combination therapy for treating acute myeloid leukemia

Info

Publication number: SG11202105197UA
Authority: SG; Singapore
Prior art keywords: venetoclax; bcl; inhibitor; combination therapy; myeloid leukemia
Prior art date: 2018-12-18

Application number

SG11202105197UA

Inventor

Haard Hans De

Samson Fung

Nicolas Leupin

Rompaey Luc Van

Adrian Ochsenbein

Carsten Riether

Original Assignee

Argenx Bvba

Univ Of Bern

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2018-12-18

Filing date

2019-12-18

Publication date

2021-07-29

2018-12-18 Priority claimed from GBGB1820582.3A external-priority patent/GB201820582D0/en

2019-08-01 Priority claimed from GBGB1911007.1A external-priority patent/GB201911007D0/en

2019-12-04 Priority claimed from GBGB1917701.3A external-priority patent/GB201917701D0/en

2019-12-18 Application filed by Argenx Bvba, Univ Of Bern filed Critical Argenx Bvba

2021-07-29 Publication of SG11202105197UA publication Critical patent/SG11202105197UA/en

Links

208000031261 Acute myeloid leukaemia Diseases 0.000 title 1
239000012664 BCL-2-inhibitor Substances 0.000 title 1
229940123711 Bcl2 inhibitor Drugs 0.000 title 1
208000033776 Myeloid Acute Leukemia Diseases 0.000 title 1
238000002648 combination therapy Methods 0.000 title 1
LQBVNQSMGBZMKD-UHFFFAOYSA-N venetoclax Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=C3C=CNC3=NC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NCC1CCOCC1 LQBVNQSMGBZMKD-UHFFFAOYSA-N 0.000 title 1
229960001183 venetoclax Drugs 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Organic Chemistry (AREA)
Epidemiology (AREA)
Immunology (AREA)
Molecular Biology (AREA)
Engineering & Computer Science (AREA)
Mycology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Endocrinology (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Microbiology (AREA)
Biophysics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Hematology (AREA)
Oncology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

SG11202105197UA 2018-12-18 2019-12-18 Cd70 and venetoclax, a bcl-2 inhibitor, combination therapy for treating acute myeloid leukemia SG11202105197UA (en)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
GBGB1820582.3A GB201820582D0 (en)	2018-12-18	2018-12-18	CD70 combination therapy
GBGB1911007.1A GB201911007D0 (en)	2019-08-01	2019-08-01	CD70 combination therapy
GBGB1917701.3A GB201917701D0 (en)	2019-12-04	2019-12-04	CD70 Combination therapy
PCT/EP2019/085982 WO2020127503A1 (en)	2018-12-18	2019-12-18	Cd70 and venetoclax, a bcl-2 inhibitor, combination therapy for treating acute myeloid leukemia

Publications (1)

Publication Number	Publication Date
SG11202105197UA true SG11202105197UA (en)	2021-07-29

Family

ID=69104399

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SG11202105197UA SG11202105197UA (en)	2018-12-18	2019-12-18	Cd70 and venetoclax, a bcl-2 inhibitor, combination therapy for treating acute myeloid leukemia

Country Status (21)

Country	Link
US (2)	US11712468B2 (en)
EP (2)	EP4218761A1 (en)
JP (1)	JP2022515077A (en)
KR (1)	KR20210106428A (en)
CN (2)	CN113226317B (en)
AU (1)	AU2019409936A1 (en)
BR (1)	BR112021011684A2 (en)
CA (1)	CA3117282A1 (en)
DK (1)	DK3890740T3 (en)
ES (1)	ES2941638T3 (en)
FI (1)	FI3890740T3 (en)
HU (1)	HUE061710T2 (en)
IL (1)	IL284015A (en)
LT (1)	LT3890740T (en)
MX (1)	MX2021007350A (en)
PL (1)	PL3890740T3 (en)
PT (1)	PT3890740T (en)
SG (1)	SG11202105197UA (en)
TW (1)	TW202038958A (en)
UY (1)	UY38511A (en)
WO (1)	WO2020127503A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TW202038958A (en)	2018-12-18	2020-11-01	比利時商阿根思公司	Cd70 combination therapy
US20220249528A1 (en) *	2019-06-20	2022-08-11	Celgene Corporation	Azacitidine in combination with venetoclax, gilteritinib, midostaurin or other compounds for treating leukemia or myelodysplastic syndrome
TW202138388A (en) *	2019-12-30	2021-10-16	美商西根公司	Methods of treating cancer with nonfucosylated anti-cd70 antibodies
EP4204098A1 (en) *	2020-08-29	2023-07-05	Argenx BV	Method of treatment of patients having reduced sensitivity to a bcl-2 inhibitor
CA3222020A1 (en) *	2021-07-21	2023-01-26	Emory University	Bak activators, pharmaceutical compositions, and uses in treating cancer
WO2023031403A1 (en) *	2021-09-02	2023-03-09	F. Hoffmann-La Roche Ag	Antibodies for the treatment of aml
WO2023081721A1 (en) *	2021-11-03	2023-05-11	Board Of Regents, The University Of Texas System	Methods relating to treatment of acute myeloid leukemia
TW202340177A (en)	2021-12-30	2023-10-16	美商拜歐米富士恩股份有限公司	Pyrazine compounds as inhibitors of flt3
CN114949230A (en) *	2022-06-13	2022-08-30	厦门大学附属第一医院	Combined pharmaceutical composition for preventing and/or treating acute myeloid leukemia and application thereof
CN117771177A (en) *	2023-08-02	2024-03-29	首都医科大学附属北京儿童医院	Venezuela self-microemulsifying drug release system and preparation method and application thereof

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5892019A (en)	1987-07-15	1999-04-06	The United States Of America, As Represented By The Department Of Health And Human Services	Production of a single-gene-encoded immunoglobulin
US5859205A (en)	1989-12-21	1999-01-12	Celltech Limited	Humanised antibodies
US5573924A (en)	1992-09-08	1996-11-12	Immunex Corporation	CD27 ligand
DE19747418C1 (en)	1997-10-27	1999-07-15	Deutsches Krebsforsch	Inhibitor protein of the wnt signaling pathway
US6500633B1 (en)	2000-04-26	2002-12-31	Atairgin Technologies, Inc.	Method of detecting carcinomas
US20030148321A1 (en)	2001-08-24	2003-08-07	Iris Pecker	Methods and kits for diagnosing and monitoring hematopoietic cancers
AU2002351828A1 (en)	2001-11-05	2003-05-19	Deutsches Krebsforschungszentrum	Novel genetic markers for leukemias
US7261892B2 (en)	2001-11-27	2007-08-28	Celltech R&D Limited	Methods for diagnosis and treatment of epithelial-derived cancers
JP4446036B2 (en)	2001-11-27	2010-04-07	ウーセーベーファルマソシエテアノニム	Pharmaceutical composition for the treatment of epithelial induced cancer
US8404716B2 (en)	2002-10-15	2013-03-26	Celgene Corporation	Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US8039218B2 (en)	2002-11-14	2011-10-18	John Wayne Cancer Institute	Detection of cancer cells in body fluids
WO2004073656A2 (en)	2003-02-20	2004-09-02	Seattle Genetics, Inc.	Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
US20080025989A1 (en)	2003-02-20	2008-01-31	Seattle Genetics, Inc.	Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
EA010350B1 (en)	2004-06-03	2008-08-29	Новиммун С.А.	Anti-cd3 antibodies and methods of use thereof
CA2583208C (en)	2004-10-15	2015-08-25	Seattle Genetics, Inc.	Anti-cd70 antibody and its use for the treatment and prevention of cancer and immune disorders
US8337838B2 (en)	2004-10-15	2012-12-25	Seattle Genetics, Inc.	Anti-CD70 antibody and its use for the treatment and prevention of cancer and immune disorders
US7641903B2 (en)	2004-10-15	2010-01-05	Seattle Genetics, Inc.	Anti-CD70 antibody and its use for the treatment and prevention of cancer and immune disorders
EP1872124A4 (en)	2005-04-19	2008-06-11	Prediction Sciences Llc	Diagnostic markers of breast cancer treatment and progression and methods of use thereof
DK1871418T3 (en)	2005-04-19	2014-06-10	Seattle Genetics Inc	Humanized anti-CD70 binding agents and uses thereof
WO2007011856A2 (en)	2005-07-15	2007-01-25	The Trustees Of Columbia University In The City Of New York	Compositions and methods for differential diagnosis of chronic lymphocytic leukemia
AU2006294663B2 (en)	2005-09-26	2012-03-22	Medarex, Inc.	Human monoclonal antibodies to CD70
US7723477B2 (en)	2005-10-31	2010-05-25	Oncomed Pharmaceuticals, Inc.	Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
KR101571027B1 (en)	2006-06-12	2015-11-23	이머전트 프로덕트 디벨롭먼트 시애틀, 엘엘씨	Single-chain multivalent binding proteins with effector function
CN101489697B (en)	2006-07-24	2011-06-01	千田建设股份有限公司	Method of descaling metal wire rod and apparatus therefor
ES2523915T5 (en)	2006-12-01	2022-05-26	Seagen Inc	Variant Target Binding Agents and Uses Thereof
EP2097534A4 (en)	2006-12-14	2010-05-12	Medarex Inc	Human antibodies that bind cd70 and uses thereof
KR100807069B1 (en)	2007-09-21	2008-02-25	고려대학교 산학협력단	Pharmaceutical composition for treating cancer
US20100267626A1 (en)	2007-11-05	2010-10-21	Novartis Ag	Methods and compositions for measuring wnt activation and for treating wnt-related cancers
GB2461546B (en)	2008-07-02	2010-07-07	Argen X Bv	Antigen binding polypeptides
WO2010014948A1 (en)	2008-08-01	2010-02-04	The University Of Utah Research Foundation	Methods of treatment using wnt inhibitors
WO2010019921A2 (en)	2008-08-15	2010-02-18	The Regents Of The University Of California	Biomarkers for diagnosis and treatment of chronic lymphocytic leukemia
WO2010037041A2 (en)	2008-09-26	2010-04-01	Oncomed Pharmaceuticals, Inc.	Frizzled-binding agents and uses thereof
ES2571235T3 (en)	2009-04-10	2016-05-24	Kyowa Hakko Kirin Co Ltd	Procedure for the treatment of a blood tumor that uses the anti-TIM-3 antibody
US8546399B2 (en)	2009-05-26	2013-10-01	Abbvie Inc.	Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
EP2987487B1 (en)	2009-08-10	2020-10-07	Samumed, LLC	Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof
WO2011035433A1 (en)	2009-09-23	2011-03-31	University Health Network	Selected strains on serum-free growth media for proteomics analysis of lung cancer biomarkers
KR101773216B1 (en)	2009-12-29	2017-08-31	교와 핫꼬 기린 가부시키가이샤	Anti-cd27 antibody
PL2581113T3 (en)	2010-06-11	2018-11-30	Kyowa Hakko Kirin Co., Ltd.	Anti-tim-3 antibody
AU2011332043C1 (en)	2010-11-23	2016-11-10	Abbvie Inc.	Salts and crystalline forms of an apoptosis-inducing agent
CA2824719C (en)	2011-01-19	2020-06-02	Cantargia Ab	Anti-il1rap antibodies and their use for treating solid tumours
ES2670874T3 (en)	2011-03-16	2018-06-01	Argenx Bvba	Antibodies against CD70
WO2013006490A2 (en)	2011-07-01	2013-01-10	Cellerant Therapeutics, Inc.	Antibodies that specifically bind to tim3
ES2806146T3 (en)	2011-09-22	2021-02-16	Amgen Inc	CD27L antigen-binding proteins
WO2013093508A2 (en)	2011-12-22	2013-06-27	Oslo University Hospital Hf	Wnt pathway inhibitors
SG10201710574UA (en)	2012-03-15	2018-02-27	Janssen Biotech Inc	Human anti-cd27 antibodies, methods and uses
AU2013237419B2 (en)	2012-03-21	2016-04-28	Erytech Pharma	Medicament for the treatment of acute myeloid leukemia (AML)
WO2013177420A2 (en)	2012-05-23	2013-11-28	St. Jude Children's Research Hospital	Methods and compositions for the treatment of bcr-abl positive lymphoblastic leukemias
JP6081582B2 (en)	2012-06-15	2017-02-15	キュアジェニックスインコーポレイテッド	Wnt signaling inhibitors, compositions and compounds as uses thereof
WO2014045101A1 (en)	2012-09-21	2014-03-27	Cellzome Gmbh	Tetrazolo quinoxaline derivatives as tankyrase inhibitors
US20150315279A1 (en)	2012-12-21	2015-11-05	Cellerant Therapeutics, Inc.	Antibodies that bind membrane-bound il1rap
PT2956173T (en)	2013-02-14	2017-06-26	Bristol Myers Squibb Co	Tubulysin compounds, methods of making and use
JOP20200096A1 (en)	2014-01-31	2017-06-16	Children’S Medical Center Corp	Antibody molecules to tim-3 and uses thereof
US10081680B2 (en)	2014-03-11	2018-09-25	The Board Of Trustees Of The Leland Stanford Junior University	Anti-SIRP-alpha antibodies and bispecific macrophage enhancing antibodies
US20160200815A1 (en)	2015-01-05	2016-07-14	Jounce Therapeutics, Inc.	Antibodies that inhibit tim-3:lilrb2 interactions and uses thereof
TWI717375B (en)	2015-07-31	2021-02-01	德商安美基研究（慕尼黑）公司	Antibody constructs for cd70 and cd3
US20180244792A1 (en)	2015-09-10	2018-08-30	University Of Pittsburgh - Of The Commonwealth System Of Higher Education	Anti-fibrotic effect of cd70
BR112018008891A8 (en)	2015-11-03	2019-02-26	Janssen Biotech Inc	antibodies that specifically bind to pd-1 and tim-3 and their uses
EA039859B1 (en)	2016-02-03	2022-03-21	Эмджен Рисерч (Мюник) Гмбх	Bispecific antibody constructs binding egfrviii and cd3
WO2017156398A1 (en)	2016-03-10	2017-09-14	Assia Chemical Industries Ltd.	Solid state forms of venetoclax and processes for preparation of venetoclax
EP3442584B1 (en)	2016-03-15	2021-07-28	Seagen Inc.	Combinations of pbd-based antibody drug conjugates with bcl-2 inhibitors
BR112018075176A2 (en)	2016-06-09	2019-06-04	Dr Reddys Laboratories Ltd	solid forms of venetoclax and processes for preparing venetoclax
WO2018009444A1 (en)	2016-07-06	2018-01-11	Concert Pharmaceuticals, Inc.	Deuterated venetoclax
CN107648185A (en)	2016-07-25	2018-02-02	常州爱诺新睿医药技术有限公司	A kind of unformed Venetoclax and pharmaceutic adjuvant solid dispersions and preparation method thereof
WO2018029711A2 (en)	2016-08-12	2018-02-15	Mylan Laboratories Limited	Process for the preparation of venetoclax
WO2018069941A2 (en)	2016-10-14	2018-04-19	Mylan Laboratories Limited	Polymorphic forms of venetoclax
EP3333167A1 (en)	2016-12-09	2018-06-13	LEK Pharmaceuticals d.d.	Solid forms of venetoclax
CZ201769A3 (en)	2017-02-06	2018-08-15	Zentiva, K.S.	Solid forms of Venetoclax
WO2018157803A1 (en)	2017-02-28	2018-09-07	苏州科睿思制药有限公司	Venetoclax crystal forms and preparation method therefor
WO2018167652A1 (en)	2017-03-13	2018-09-20	Laurus Labs Limited	Process for preparation of amorphous form of venetoclax
CN107089981A (en)	2017-04-24	2017-08-25	杭州科耀医药科技有限公司	A kind of inhibitor Venetoclax of BCL 2 synthetic method
GB2567613A (en)	2017-06-16	2019-04-24	Argenx Bvba	Treatment for acute myeloid leukaemia
GB201800649D0 (en)	2018-01-16	2018-02-28	Argenx Bvba	CD70 Combination Therapy
TW202038958A (en)	2018-12-18	2020-11-01	比利時商阿根思公司	Cd70 combination therapy

2019
- 2019-12-16 TW TW108146057A patent/TW202038958A/en unknown
- 2019-12-17 UY UY0001038511A patent/UY38511A/en unknown
- 2019-12-18 LT LTEPPCT/EP2019/085982T patent/LT3890740T/en unknown
- 2019-12-18 EP EP23151526.3A patent/EP4218761A1/en active Pending
- 2019-12-18 ES ES19831677T patent/ES2941638T3/en active Active
- 2019-12-18 FI FIEP19831677.0T patent/FI3890740T3/en active
- 2019-12-18 DK DK19831677.0T patent/DK3890740T3/en active
- 2019-12-18 US US16/719,220 patent/US11712468B2/en active Active
- 2019-12-18 CN CN201980082377.7A patent/CN113226317B/en active Active
- 2019-12-18 CA CA3117282A patent/CA3117282A1/en active Pending
- 2019-12-18 KR KR1020217017438A patent/KR20210106428A/en unknown
- 2019-12-18 PT PT198316770T patent/PT3890740T/en unknown
- 2019-12-18 PL PL19831677.0T patent/PL3890740T3/en unknown
- 2019-12-18 BR BR112021011684A patent/BR112021011684A2/en unknown
- 2019-12-18 WO PCT/EP2019/085982 patent/WO2020127503A1/en unknown
- 2019-12-18 MX MX2021007350A patent/MX2021007350A/en unknown
- 2019-12-18 CN CN202211004780.8A patent/CN115920034A/en active Pending
- 2019-12-18 AU AU2019409936A patent/AU2019409936A1/en active Pending
- 2019-12-18 HU HUE19831677A patent/HUE061710T2/en unknown
- 2019-12-18 JP JP2021534948A patent/JP2022515077A/en active Pending
- 2019-12-18 EP EP19831677.0A patent/EP3890740B1/en active Active
- 2019-12-18 SG SG11202105197UA patent/SG11202105197UA/en unknown
2021
- 2021-06-15 IL IL284015A patent/IL284015A/en unknown
2023
- 2023-06-14 US US18/334,582 patent/US20240033353A1/en active Pending

Also Published As

Publication number	Publication date
KR20210106428A (en)	2021-08-30
CN113226317B (en)	2022-08-16
AU2019409936A1 (en)	2021-05-27
US11712468B2 (en)	2023-08-01
PL3890740T3 (en)	2023-07-24
EP3890740B1 (en)	2023-03-01
US20240033353A1 (en)	2024-02-01
HUE061710T2 (en)	2023-08-28
FI3890740T3 (en)	2023-05-24
CA3117282A1 (en)	2020-06-25
EP4218761A1 (en)	2023-08-02
BR112021011684A2 (en)	2021-11-30
JP2022515077A (en)	2022-02-17
US20200222532A1 (en)	2020-07-16
CN113226317A (en)	2021-08-06
IL284015A (en)	2021-08-31
MX2021007350A (en)	2021-09-21
LT3890740T (en)	2023-03-27
WO2020127503A1 (en)	2020-06-25
UY38511A (en)	2020-07-31
EP3890740A1 (en)	2021-10-13
TW202038958A (en)	2020-11-01
DK3890740T3 (en)	2023-05-08
ES2941638T3 (en)	2023-05-24
CN115920034A (en)	2023-04-07
PT3890740T (en)	2023-05-15

Publication	Publication Date	Title
IL284015A (en)	2021-08-31	Cd70 and venetoclax, a bcl-2 inhibitor, combination therapy for treating acute myeloid leukemia
IL277435A (en)	2020-11-30	Substituted 4-aminoisoindoline-1,3-dione compounds and their use for treating lymphoma
EP3436014A4 (en)	2019-11-27	Combination therapy for the treatment of acute myeloid leukemia
IL275949A (en)	2020-08-31	Combination therapy for treating or preventing cancer
SG11202006893WA (en)	2020-08-28	Disrupting the linc complex for treating laminopathy
PH12018501943A1 (en)	2019-06-17	Pharmaceutical compositions for the treatment of cancer
ZA202204657B (en)	2022-07-27	Compounds, compositions, and methods for treating t-cell acute lymphoblastic leukemia
EP4121051A4 (en)	2024-04-17	Combination therapy for acute myeloid leukemia
IL288864A (en)	2022-02-01	Treatment comprising sglt inhibitors, e.g. sglt 1/2 inhibitors
EP3615020A4 (en)	2021-01-20	Methods, agents, and compositions for the treatment of acute myeloid leukemia
IL288178A (en)	2022-01-01	Gmci and ddri combination therapy for treating cancer
IL286680A (en)	2021-10-31	Medicament for treating cancer
IL276074A (en)	2020-08-31	Combination therapy for treating or preventing cancer
IL276073A (en)	2020-08-31	Combination therapy for treating or preventing cancer
IL275860A (en)	2020-08-31	Combination therapy for treating or preventing cancer
EP3982954A4 (en)	2024-01-03	Nt5c2 inhibitors for the treatment of chemotherapy-resistant acute lymphoblastic leukemia
EP3880205C0 (en)	2023-08-30	Madrasin-derivative compounds, composition and uses thereof for treating cancer
GB201808636D0 (en)	2018-07-11	Combination therapy for treating or preventing cancer
GB201808632D0 (en)	2018-07-11	Combination therapy for treating or preventing cancer
GB201808628D0 (en)	2018-07-11	Combination therapy for treating or preventing cancer
GB201808631D0 (en)	2018-07-11	Combination therapy for treating or preventing cancer
EP3886833A4 (en)	2022-08-17	Therapeutic methods and compositions for treating acute myeloid leukemia using devimistat
GB201806572D0 (en)	2018-06-06	Combination therapy for treating or preventing cancer
GB201805941D0 (en)	2018-05-23	Combination therapy for treating or preventing cancer
GB201801502D0 (en)	2018-03-14	Combination therapy for treating or preventing cancer